Advances in Treatment of Leukemia
A special issue of Bioengineering (ISSN 2306-5354). This special issue belongs to the section "Biomedical Engineering and Biomaterials".
Deadline for manuscript submissions: closed (31 December 2023) | Viewed by 14547
Special Issue Editor
Special Issue Information
Dear Colleagues,
Leukemia is a heterogenous cancer of blood-forming cells, including the bone marrow and the lymphatic system. It could be classified as myelocytic or lymphocytic based on the cell of origin. However, novel therapeutic agents are lacking for leukemia treatment because of its diverse pathogenesis. Bioengineering technologies such as CAR-T, antibody–drug conjugates (ADC), cancer vaccines, and nuclear acid drugs have been developed for the treatment of leukemia during the past few decades. These bioengineering technologies utilize the unique properties of biomacromolecule or immune cells and could specifically deliver drugs into leukemia cells or induce immune response, resulting in leukemia cell death. Compared with traditional chemotherapy drugs, bioengineering drugs have exhibited better biocompatibility and are becoming a promising area for leukemia treatment.
This Special Issue on “Advances in Treatment of Leukemia” focuses on original research papers and comprehensive reviews which investigate multiscale novel bioengineering technologies for effective leukemia treatment.
Dr. Hua Naranmandura
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Bioengineering is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.